Fact Source: Financial Supervisory Service DART / 2026-03-26
Disclosure Type: Submission of Audit Report (Correction)
💡 3-Second Summary
This is a corrective disclosure by Samsung Biologics to fix a simple typographical error regarding the fiscal year end dates in its previously filed audit report. There are no changes to the financial figures, and the consolidated operating profit stands firm at approximately KRW 2.07T with an unqualified ‘Clean’ audit opinion.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Correction: Rectified a typographical error in the fiscal year end date under the separate financial statements section (Before: 당해 2025-12-01, 직전 2024-12-01 → After: 당해 2025-12-31, 직전 2024-12-31).
- Audit Opinion: Conducted by KPMG Samjong Accounting Corp., receiving an ‘Unqualified (Clean)’ opinion for both consolidated and separate statements for the current and prior fiscal years (No material uncertainty related to going concern).
- Key Consolidated Financials (KRW):
- Revenue: KRW 4,556,971,695,180 (Prior Year: KRW 3,497,145,675,782)
- Operating Profit: KRW 2,069,221,266,630 (Prior Year: KRW 1,321,366,380,588)
- Net Income: KRW 1,784,352,060,593 (Prior Year: KRW 1,083,315,885,986)
- Key Separate Financials (KRW):
- Revenue: KRW 4,556,971,695,180
- Operating Profit: KRW 2,068,092,839,427
- Net Income: KRW 1,586,186,963,312
- Other Details: The number of consolidated subsidiaries is 11. No embezzlement or breach of trust was reported. No capital impairment. The audit report was received on 2026-02-25, and figures may subject to change during the upcoming general shareholders’ meeting approval process. The disclosure does not state specific reasons for the change in earnings.
📈 2. [Expert View: What This Disclosure Means for Investors]
This filing is a purely administrative correction regarding the closing date of the fiscal year, rather than a material accounting error or an earnings revision. Crucial fundamental metrics, including consolidated revenue (approx. KRW 4.56T) and consolidated operating profit (approx. KRW 2.07T), remain completely identical to the previous release.
Since the audit opinion firmly remains ‘Unqualified’, any potential risk regarding accounting transparency is likely to be negligible. While the data confirms significant year-over-year growth compared to the prior fiscal year, the filing does not clarify the specific drivers behind this performance change. Investors should note that minor adjustments could occur during the final shareholder approval process; however, because no negative fundamental catalysts have been identified, it is reasonable to focus on the strong, verified financial numbers rather than the clerical correction itself.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ latest filing simply adjusts the stated fiscal year end from ‘December 1st’ to the correct ‘December 31st’. While global investors scanning regulatory updates might have felt a brief moment of caution upon seeing a ‘Correction’ tag, the core fundamental reality—a stellar operating profit crossing the KRW 2T mark—remains completely intact alongside a clean bill of health from KPMG Samjong. No negative indicators regarding internal controls or corporate governance were triggered. The numbers will become legally finalized post the general shareholders’ meeting, so maintaining a baseline observation until then is recommended, though the administrative amendment itself requires no strategic overreaction.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
